Exploring Mechanisms of Action & Navigating Agent Synergy in the Pre-clinic to Improve the Efficacy of Combination Therapies
Time: 2:30 pm
day: Workshop E
Details:
Current pre-clinical exploration in combination strategies for targeting RAS-driven tumors is underscored by selecting synergistic agents with complementary mechanisms to overcome acquired resistance. Amidst the emergence of diverse modalities, a deeper understanding of the interplay between targeted proteins and up/downstream pathways is crucial, alongside toxicity risks. This workshop will shed light on promising combinations in pre-clinical models, debate novel drug pairs and direct/indirect co-treatments. These insights will drive the optimization of combination regimens to advance personalized cancer treatment paradigms for patients with unmet need.
This workshop will discuss:
• How to effectively identify synergistic agents with complementary mechanisms of action?
• What current combinations are being tested and how have these preformed?
• How to mitigate toxicity risks associated with combination therapies?
• How to translate promising pre-clinical findings into clinically viable combination regimens?
